Clinical Trial

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-06.
Trial Details
NCT Number NCT06971614
Lead Sponsor ImmVira Pharma Co. Ltd
Conditions Nonmuscle-invasive Bladder Cancer
Enrollment 160 participants
Start Date 2025-06-09
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-23